Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HA6722
- Development stage
- Preclinical
- Lead developer
- Academy of Military Medical Sciences
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
HA6722 is a 20-mer phosphorothioate antisense oligodeoxynucleotide (ASO) designed to target and downregulate human epidermal growth factor receptor 2 (HER2, also known as ERBB2) mRNA. By hybridizing with complementary sequences of HER2 mRNA, HA6722 induces RNase H-mediated degradation of the transcript, thereby inhibiting HER2 protein expression and suppressing the proliferation of HER2-overexpressing breast cancer cells. Preclinical studies have demonstrated that HA6722 inhibits tumor growth in vitro and in vivo, and acts synergistically as a chemosensitizer when combined with docetaxel.
- Other names
- ASO HA6722ASO-HA6722ASO-HA-6722ASO-HA 6722antisense oligodeoxynucleotide HA6722HER2-specific antisense oligodeoxynucleotide HA6722HER-2-specific antisense oligodeoxynucleotide HA6722HER 2-specific antisense oligodeoxynucleotide HA6722
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HA6722.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HA6722.